Nanolek and Chumakov Center plans to meet demand for CoviVac in Russia

Russian drugmaker Nanolek continues the production of CoviVac, the vaccine which was developed by the country’s Chumakov Federal Scientific Center, reports The Pharma Letter’s local correspondent.

In the summer of 2021, low volume of production of this vaccine caused a rush of demand in Russia. Now the Chumakov Center has more than doubled the production of the mixture for bottling the vaccine, that will allow Nanolek to utilize long-prepared lines. The Russian Health Ministry registered the whole-virion CoviVac vaccine in February 2021, making it the third Russian-developed COVID-19 vaccine.

Vladimir Khristenko, head of Nanolek, earlier said in an interview with Forbes Russia magazine, the company launched the production of the vaccine in December, 2021. Previously the production was only conducted at Chumakov Center, which in recent months has significantly expanded its capacities, which are currently capable to produce about 20 million doses of the vaccine a year.